AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

- 1-4. (Cancelled)
- 5. (Currently amended) A medical device configured to deliver a first and a second drug to a blood vessel to reduce the degree or substantially prevent the occurrence of restenosis in the blood vessel, said first <u>drug being epothilone D</u> and <u>said second drug being drugs selected from the group consisting of epothilone D</u>, rapamycin[[,]] <u>or</u> a rapamycin analog, 17-allylamino-17-desmethoxygeldanamycin, 17-[2-(dimethylamino)ethylamino]-17-desmethoxy-11-O-methylgeldanamycin, and 17-azetidinyl-17-desmethoxygeldanamycin; wherein said first and second drugs show synergistic cytotoxic activity.
- 6. (Original) The medical device of Claim 5 wherein the medical device is a stent or polymer wrapper
- 7-13. (Cancelled)
- 14. (Currently Amended) A composition comprising a polymer and a first and second drug, said first drug being epothilone D and said second drug being drugs selected from the group consisting of epothilone D, rapamycin[[,]] or a rapamycin analog, 17-allylamino-17-desmethoxygeldanamycin, 17-[2 (dimethylamino)ethylamino]-17-desmethoxy-geldanamycin, 17-[2 (dimethylamino)ethylamino]-17-desmethoxy-11-O-methylgeldanamycin, and 17-azetidinyl-17-desmethoxygeldanamycin; wherein said first and second drugs show synergistic cytotoxic activity.
- 15-18. (Cancelled)

- 19. (Currently Amended) The composition of Claim 13 14 wherein the polymer is selected from the group consisting of a polylactide, a photo-curable poly(ester-amide), and a polyurethane.
- 20. (Currently Amended) A method to reduce the degree or substantially prevent restenosis in a blood vessel, comprising delivering a composition of Claim 13 14 to a blood vessel requiring treatment for, or prevention of, restenosis, in an amount sufficient to substantially reduce, or substantially prevent, restenosis in such blood vessel.